{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:20:56Z","timestamp":1775060456680,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,30]]},"DOI":"10.7759\/cureus.81476","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:10:00Z","timestamp":1743383400000},"source":"Crossref","is-referenced-by-count":3,"title":["A Natural Course From Primary Intraocular Lymphoma to Brain Lymphoma in Four Years According to Patient's Choice"],"prefix":"10.7759","author":[{"given":"Toshihiko","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2598","article-title":"Primary central nervous system lymphoma: a curable disease","volume":"37","author":"Batchelor TT","year":"2019","unstructured":"Batchelor TT. Primary central nervous system lymphoma: a curable disease. Hematol Oncol. 2019, 37:15-8. 10.1002\/hon.2598","journal-title":"Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri AJ","year":"2023","unstructured":"Ferreri AJ, Calimeri T, Cwynarski K, et al.. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023, 9:29. 10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1776783","article-title":"Central nervous system lymphoma","volume":"43","author":"Shah T","year":"2023","unstructured":"Shah T, Venur VA. Central nervous system lymphoma. Semin Neurol. 2023, 43:825-32. 10.1055\/s-0043-1776783","journal-title":"Semin Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff LR","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022, 140:971-9. 10.1182\/blood.2020008377","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan K","year":"2023","unstructured":"Hoang-Xuan K, Deckert M, Ferreri AJ, et al.. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023, 25:37-53. 10.1093\/neuonc\/noac196","journal-title":"Neuro Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.020","article-title":"High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry","volume":"25","author":"Kondo E","year":"2019","unstructured":"Kondo E, Ikeda T, Izutsu K, et al.. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant. 2019, 25:899-905. 10.1016\/j.bbmt.2019.01.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03263-y","article-title":"An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma","volume":"115","author":"Nishikori M","year":"2022","unstructured":"Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, Kondo E. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022, 115:391-8. 10.1007\/s12185-021-03263-y","journal-title":"Int J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.22007","article-title":"CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy","volume":"62","author":"Matsuo T","year":"2022","unstructured":"Matsuo T, Tanaka T, Fujii N, Fujii K, Kondo E. CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy. J Clin Exp Hematop. 2022, 62:187-9. 10.3960\/jslrt.22007","journal-title":"J Clin Exp Hematop"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.65.622","article-title":"Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation [Article in Japanese]","volume":"65","author":"Fujii F","year":"2024","unstructured":"Fujii F, Terao T, Nishimori H, et al.. Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation [Article in Japanese]. Rinsho Ketsueki. 2024, 65:622-7. 10.11406\/rinketsu.65.622","journal-title":"Rinsho Ketsueki"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain C","year":"2021","unstructured":"Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021, 138:1519-34. 10.1182\/blood.2020008235","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199807000-00002","article-title":"Two types of initial ocular manifestations in intraocular-central nervous system lymphoma","volume":"18","author":"Matsuo T","year":"1998","unstructured":"Matsuo T, Yamaoka A, Shiraga F, Matsuo N. Two types of initial ocular manifestations in intraocular-central nervous system lymphoma. Retina. 1998, 18:301-7. 10.1097\/00006982-199807000-00002","journal-title":"Retina"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.49.77","article-title":"Positron emission tomography\/computed tomography after immunocytochemical and clonal diagnosis of intraocular lymphoma with vitrectomy cell blocks","volume":"49","author":"Matsuo T","year":"2009","unstructured":"Matsuo T, Ichimura K, Ichikawa T, Okumura Y, Kaji M, Yoshino T. Positron emission tomography\/computed tomography after immunocytochemical and clonal diagnosis of intraocular lymphoma with vitrectomy cell blocks. J Clin Exp Hematop. 2009, 49:77-87. 10.3960\/jslrt.49.77","journal-title":"J Clin Exp Hematop"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.19019","article-title":"Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?","volume":"59","author":"Matsuo T","year":"2019","unstructured":"Matsuo T, Tanaka T. Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?. J Clin Exp Hematop. 2019, 59:168-74. 10.3960\/jslrt.19019","journal-title":"J Clin Exp Hematop"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.4755","article-title":"Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study","volume":"133","author":"Riemens A","year":"2015","unstructured":"Riemens A, Bromberg J, Touitou V, et al.. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015, 133:191-7. 10.1001\/jamaophthalmol.2014.4755","journal-title":"JAMA Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14848","article-title":"Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma","volume":"179","author":"Kaburaki T","year":"2017","unstructured":"Kaburaki T, Taoka K, Matsuda J, et al.. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol. 2017, 179:246-55. 10.1111\/bjh.14848","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.55.157","article-title":"Intraocular relapse with hypopyon and retinal infiltrates after chemotherapy and peripheral blood stem cell transplantation for extranodal NK\/T-cell lymphoma","volume":"55","author":"Matsuo T","year":"2015","unstructured":"Matsuo T, Tanaka T, Ichimura K, Meguri Y. Intraocular relapse with hypopyon and retinal infiltrates after chemotherapy and peripheral blood stem cell transplantation for extranodal NK\/T-cell lymphoma. J Clin Exp Hematop. 2015, 55:157-61. 10.3960\/jslrt.55.157","journal-title":"J Clin Exp Hematop"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620966843","article-title":"Pathologically proven intraocular infiltration with adult T-cell leukemia\/lymphoma: two new cases with either vitreous opacity or aqueous hypopyon and literature review of 16 cases","volume":"8","author":"Matsuo T","year":"2020","unstructured":"Matsuo T, Shimizu T, Tanaka T, Yamamoto A, Takasuka H. Pathologically proven intraocular infiltration with adult T-cell leukemia\/lymphoma: two new cases with either vitreous opacity or aqueous hypopyon and literature review of 16 cases. J Investig Med High Impact Case Rep. 2020, 8:2324709620966843. 10.1177\/2324709620966843","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.18026","article-title":"Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma","volume":"58","author":"Matsuo T","year":"2018","unstructured":"Matsuo T, Tanaka T, Yano T. Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma. J Clin Exp Hematop. 2018, 58:180-3. 10.3960\/jslrt.18026","journal-title":"J Clin Exp Hematop"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.10.020","article-title":"Immunocytochemical diagnosis as inflammation by vitrectomy cell blocks in patients with vitreous opacity","volume":"119","author":"Matsuo T","year":"2012","unstructured":"Matsuo T, Ichimura K. Immunocytochemical diagnosis as inflammation by vitrectomy cell blocks in patients with vitreous opacity. Ophthalmology. 2012, 119:827-37. 10.1016\/j.ophtha.2011.10.020","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01102-1","article-title":"Clinical features and multimodal imaging of primary choroidal lymphoma","volume":"68","author":"Goto H","year":"2024","unstructured":"Goto H, Umazume K, Usui Y, Nishikawa N. Clinical features and multimodal imaging of primary choroidal lymphoma. Jpn J Ophthalmol. 2024, 68:722-30. 10.1007\/s10384-024-01102-1","journal-title":"Jpn J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351442-a-natural-course-from-primary-intraocular-lymphoma-to-brain-lymphoma-in-four-years-according-to-patients-choice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:10:01Z","timestamp":1743383401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351442-a-natural-course-from-primary-intraocular-lymphoma-to-brain-lymphoma-in-four-years-according-to-patients-choice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.81476","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}